(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US-11084810-B2 · Aug 10, 2021 · US
(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US11725004B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11725004-B2 |
| Application number | US-202117398155-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 10, 2021 |
| Priority date | May 17, 2013 |
| Publication date | Aug 15, 2023 |
| Grant date | Aug 15, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating diabetic neuropathy, comprising administering to a human being an effective amount of a compound selected from the group consisting of and a pharmaceutically acceptable salt thereof, to treat the diabetic neuropathy. 2. The method of claim 1 , wherein the compound is 3. The method of claim 1 , wherein the compound is administered in the form of a tablet, pill, or capsule. 4. The method of claim 2 , wherein the compound is administered in the form of a tablet, pill, or capsule. 5. A method of treating neuropathic pain due to diabetic peripheral neuropathy, comprising administering to a human being an effective amount of a compound selected from the group consisting of and a pharmaceutically acceptable salt thereof, to treat the neuropathic pain due to diabetic peripheral neuropathy. 6. The method of claim 5 , wherein the compound is 7. The method of claim 5 , wherein the compound is administered in the form of a tablet, pill, or capsule. 8. The method of claim 6 , wherein the compound is administered in the form of a tablet, pill, or capsule. 9. A method of treating neuropathic pain due to diabetic neuropathy, comprising administering to a human being an effective amount of a compound selected from the group consisting of and a pharmaceutically acceptable salt thereof, to treat the neuropathic pain due to diabetic neuropathy. 10. The method of claim 9 , wherein the compound is 11. The method of claim 9 , wherein the compound is administered in the form of a tablet, pill, or capsule. 12. The method of claim 10 , wherein the compound is administered in the form of a tablet, pill, or capsule. 13. A method of treating nerve injury-induced neuropathic pain, comprising administering to a human being an effective amount of a compound selected from the group consisting of and a pharmaceutically acceptable salt thereof, to treat the nerve injury-induced neuropathic pain. 14. The method of claim 13 , wherein the compound is 15. The method of claim 13 , wherein the compound is administered in the form of a tablet, pill, or capsule. 16. The method of claim 14 , wherein the compound is administered in the form of a tablet, pill, or capsule.
Assignees
Inventors
Classifications
- C07D417/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
not condensed and containing further heterocyclic rings · CPC title
having one double bond between ring members or between a ring member and a non-ring member · CPC title
Nitrogen atoms · CPC title
containing two hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11725004B2 cover?
- This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
- Who is the assignee on this patent?
- Centrexion Therapeutics Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D417/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).